Acute regulation of cardiac metabolism by the hexosamine biosynthesis pathway and protein O-GlcNAcylation - PubMed (original) (raw)

Acute regulation of cardiac metabolism by the hexosamine biosynthesis pathway and protein O-GlcNAcylation

Boglárka Laczy et al. PLoS One. 2011.

Abstract

Objective: The hexosamine biosynthesis pathway (HBP) flux and protein O-linked N-acetyl-glucosamine (O-GlcNAc) levels have been implicated in mediating the adverse effects of diabetes in the cardiovascular system. Activation of these pathways with glucosamine has been shown to mimic some of the diabetes-induced functional and structural changes in the heart; however, the effect on cardiac metabolism is not known. Therefore, the primary goal of this study was to determine the effects of glucosamine on cardiac substrate utilization.

Methods: Isolated rat hearts were perfused with glucosamine (0-10 mM) to increase HBP flux under normoxic conditions. Metabolic fluxes were determined by (13)C-NMR isotopomer analysis; UDP-GlcNAc a precursor of O-GlcNAc synthesis was assessed by HPLC and immunoblot analysis was used to determine O-GlcNAc levels, phospho- and total levels of AMPK and ACC, and membrane levels of FAT/CD36.

Results: Glucosamine caused a dose dependent increase in both UDP-GlcNAc and O-GlcNAc levels, which was associated with a significant increase in palmitate oxidation with a concomitant decrease in lactate and pyruvate oxidation. There was no effect of glucosamine on AMPK or ACC phosphorylation; however, membrane levels of the fatty acid transport protein FAT/CD36 were increased and preliminary studies suggest that FAT/CD36 is a potential target for O-GlcNAcylation.

Conclusion/interpretation: These data demonstrate that acute modulation of HBP and protein O-GlcNAcylation in the heart stimulates fatty acid oxidation, possibly by increasing plasma membrane levels of FAT/CD36, raising the intriguing possibility that the HBP and O-GlcNAc turnover represent a novel, glucose dependent mechanism for regulating cardiac metabolism.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1

Figure 1. Effect of glucosamine on A, B) Overall cardiac O-GlcNAc levels; C) UDP-HexNAc concentrations and D) ATP concentrations.

* P<0.05 vs. 0 mM, one-way ANOVA with Dunnett's posthoc test. Western blots: 0 mM (n = 8), 0.05 mM (n = 5), 0.1 mM (n = 9), 1 mM (n = 4), 5 mM (n = 8), 10 mM (n = 7). HPLC: 0 mM (n = 4), 0.05 mM (n = 5), 0.1 mM (n = 5), 1 mM (n = 4), 5 mM (n = 3), 10 mM (n = 3). Note that equal protein loading for the O-GlcNAc immunoblots was assessed by Sypro staining and overall O-GlcNAc levels were normalized to untreated control group.

Figure 2

Figure 2. Effect of glucosamine on A) glucose; B) pyruvate; C) lactate and D) palmitate oxidation.

* P<0.05 vs. 0 mM glucosamine, one-way ANOVA with Dunnett's posthoc test. 0 mM (n = 6), 0.05 mM (n = 4), 0.1 mM (n = 5), 5 mM (n = 5), 10 mM (n = 4).

Figure 3

Figure 3. Effect of 0.1 mM glucosamine on A) unlabeled glycolytic lactate efflux and B) exogenous [3-13C]lactate uptake * P<0.05 vs. 0 mM, Student's t-test.

0 mM (n = 4), 0.1 mM (n = 5).

Figure 4

Figure 4. A) AMPK and B) ACC phosphorylation in the heart after 60 min perfusion with 0.1 mM glucosamine.

0 mM (n = 4), 0.1 mM (n = 5).

Figure 5

Figure 5. A) Immunoblots of Plasma membrane fraction for FAT/CD36 following 60 min perfusion with 0, 0.05, 0.1, 1, 5 and 10 mM; pan-cadherin included as a plasma membrane marker and protein loading control; B) Densitometric analysis of FAT/CD36 immunoblots normalized to 0 mM glucosamine; P<0.05 vs. 0 mM, one-way ANOVA with Dunnett's posthoc test; n = 2 in each group; C) Immunoprecipitation of FAT/CD36 from whole tissue and plasma membrane lysates, followed by O-GlcNAc and OGT immunoblots.

Specificity of O-GlcNAc antibody was confirmed by co-incubation with 10 mM N-acetylglucosamine (GlcNAc).

Similar articles

Cited by

References

    1. An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2006;291:H1489–1506. - PubMed
    1. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115:3213–3223. - PubMed
    1. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle: Its role in insulin sensitivity and metabolic disturbances of diabetes mellitus. The Lancet. 1963;1:785–789. - PubMed
    1. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology. 2005;146:5341–5349. - PubMed
    1. Torres CR, Hart GW. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem. 1984;259:3308–3317. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources